Gain Therapeutics IncGANX
Price$1.72

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$20.1MTTM through 30 Jun 2026
Free Cash Flow -$19MTTM through 30 Jun 2026

Margins

Current

Returns

-108.6%ROE
-88.3%ROA

Balance Sheet Health

Debt / Equity0.02x
Current Ratio6.63x
Net Debt-$20.4Mnet cash position
Cash & Equivalents$13.1M

Quality Metrics

Altman Z-Score-1.00
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'20'21'22'23
FY2023: $55.2K
Diluted EPS-$0.50TTM
'20'21'22'23'24'25
FY2025: $-0.61

Dividend

No dividend

Capital Allocation

R&D Spend$10.1M

Segment Performance

SegmentRevenueYoYOutlook
Allosteric Therapies Discovery and Development$0
View details

Phase 2 clinical trial is planned to commence in the second half of 2026 pending IND clearance.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.